A note on ethno-myco-medicines from central India

Kumar, Brajesh; Ayachi, Shiv Shanker; Rai, Arvinder

doi:10.1016/s0269-915x(09)80397-2

Cited by 21 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This potential access problem had been noted in the synthetic biology context. 108 However, the new approach to isolated DNA under the Supreme Court's decision in Myriad means that although standard biological parts may cover sequences of patented DNA, those patents can no longer be enforced. The infringement potential has now been negated under this decision.…”

Section: B Genetic Sequencesmentioning

confidence: 99%

Patent Law and the Emerging Science of Synthetic Biology: An Examination of Principle and Practice

McLennan¹

2017

Biotechnology Law Report

View full text Add to dashboard Cite

This article considers how the longstanding debate about patent law and biotechnology is playing out in the emerging field of synthetic biology. Synthetic biology draws on molecular biotechnology, chemical engineering, genomics, and information technology to create new tools and techniques with the potential to yield transformative applications in energy, medicine, and many other areas. There has been concern that very broad patents in synthetic biology could impede the development of innovative products and public access to them, thwarting the policy goals of the patent system. Some synthetic biologists are seeking patents, while others are sharing their work in order to avoid the pitfalls of the patent system. The article investigates whether synthetic biology raises new intellectual property issues, and whether law reform or new policies are required. It analyzes the likely impact of key United States case law, such as the Myriad decision on the patentability of synthetic biology technologies. The article argues that the major processes and tools in synthetic biology are likely to meet the legal tests for patentable subject matter. It then presents a detailed case study of the examination practices of the United States Patent and Trademark Office in relation to patent families filed by scientists at the J. Craig Venter Institute. The case study shows the patent system to be working well to narrow the scope of broad claims and avoid granting patents for technology too early in its development. The article further argues that there are significant differences between synthetic biology and earlier controversial subject matter, such as human genes and genetic tests. It concludes that while synthetic biology patents do pose possible risks to the goals of the patent system, they are likely to be less problematic in this regard than patents on earlier genetic technologies.

show abstract

Section: B Genetic Sequencesmentioning

confidence: 99%

Patent Law and the Emerging Science of Synthetic Biology: An Examination of Principle and Practice

McLennan¹

2017

Biotechnology Law Report

View full text Add to dashboard Cite

show abstract

“…The traditional use of puffballs (Lycoperdales and Tulostomatales) for medicinal purposes is universal (Birks, 1991). To cite just a few examples of this ethnomycological use of medicinal mushrooms, Harsh et al (1999) and Rai et al (1993) found wide ethnomycological knowledge and use of medicinal fungi among tribes from Madhya Pradesh, in India. Among the species used were Agaricus sp.…”

Section: The Medicinal Value Of Fungimentioning

confidence: 99%

The Contribution of Wild Fungi to Diet, Income and Health: A World Review

Román

2010

Progress in Mycology

View full text Add to dashboard Cite

“…(Swanton, 1917;Patouillard, 1924;Rolfe and Rolfe, 1925;Watling and Steward, 1976;Oso, 1977;Dickenson and Lucas, 1979;Burk, 1983;Liu, 1984;Morris, 1987;Rai et al, 1993;Guzmán, 1994;Kawahara et al, 1994;Laessoe and Spooner, 1994).…”

Section: Pharmaceutical Investigationsmentioning

confidence: 99%

The genus Calvatia (Gasteromycetes, Lycoperdaceae): A review of its ethnomycology and biotechnological potential

Coetzee¹,

Wyk²

2009

Afr. J. Biotechnol.

View full text Add to dashboard Cite

Several members of the fungal puffball genus Calvatia Fr. have found widespread use amongst various cultures world-wide, especially as sources of food and/or traditional medicine. Hitherto the biotechnological potential of only a handful of Calvatia species, namely C. cyathiformis, C. craniiformis, C. excipuliformis, C. gigantea and C. utriformis has been investigated. However, despite promising results, information regarding the biotechnological potential of the rest of the genus, in particular the African species, is still completely lacking. In the hope that it might stimulate interest and further research on this topic, the current paper provides a brief overview of the literature pertaining to the importance of Calvatia to man in terms of its pathogenicity, its ecology and role as bioindicator, its food and nutritional value and also its potential as biotechnological tool in the pharmaceutical and other industries.

show abstract

A note on ethno-myco-medicines from central India

Cited by 21 publications

References 4 publications

Patent Law and the Emerging Science of Synthetic Biology: An Examination of Principle and Practice

Patent Law and the Emerging Science of Synthetic Biology: An Examination of Principle and Practice

The Contribution of Wild Fungi to Diet, Income and Health: A World Review

The genus Calvatia (Gasteromycetes, Lycoperdaceae): A review of its ethnomycology and biotechnological potential

Contact Info

Product

Resources

About